Stay updated on Efficacy Safety Rituximab + Omalizumab Clinical Trial
Sign up to get notified when there's something new on the Efficacy Safety Rituximab + Omalizumab Clinical Trial page.

Latest updates to the Efficacy Safety Rituximab + Omalizumab Clinical Trial page
- Check3 days agoChange DetectedWithdrawn status is displayed for the study, and several regulatory disclosures (FDA-regulated product indicators, IPD sharing plans) have been removed. Related details such as PI/IRB status and regulatory notes are no longer visible.SummaryDifference17%

- Check10 days agoChange DetectedThe only change is a footer revision label updated to Revision: v3.3.4 (replacing v3.3.3); this is a minor, technical update and does not affect study details, data, or user-facing content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check31 days agoChange DetectedLocations now include California under Locations. The California Locations entry and HHS Vulnerability Disclosure link were removed, and the page revision updated to v3.3.3.SummaryDifference0.2%

- Check53 days agoChange DetectedRevision: v3.3.2 replacing v3.3.1. No visible changes to study content are indicated.SummaryDifference0.1%

- Check60 days agoChange DetectedRevision: v3.3.1 replaces the previous v3.2.0 on the page. No changes to study details, eligibility, or outcome measures are evident.SummaryDifference0.1%

- Check68 days agoChange DetectedThe site removed the government funding status notice that used to appear on this page, and the core study details remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Efficacy Safety Rituximab + Omalizumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efficacy Safety Rituximab + Omalizumab Clinical Trial page.